391 results on '"Armstrong, Paul W."'
Search Results
2. Age, Sex, and Outcomes in Heart Failure With Reduced EF
3. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
4. Predicting Heart Failure With Reduced or Preserved Ejection Fraction From Health Records
5. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
6. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction
7. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
8. Sequential Evaluation of NT-proBNP in Heart Failure
9. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat
10. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry
11. Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Health Services Users
12. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
13. Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy
14. Reply
15. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
16. Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy
17. In Memoriam: James T. Willerson, 1939 to 2020
18. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
19. Non-participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry
20. The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients
21. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
22. Long-Term Outcomes of Complete Revascularization With Percutaneous Coronary Intervention in Acute Coronary Syndromes
23. High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction
24. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
25. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
26. Prognostic Implications of Changes in Amino-Terminal Pro–B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF
27. Sex And Prognostic Significance of Self-Reported Frailty in Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial
28. 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion
29. Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF)
30. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
31. Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial
32. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study
33. Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis
34. Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction
35. Traveling the Interstices of Data Sharing
36. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
37. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure
38. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy
39. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
40. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator
41. Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis
42. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease
43. A Natural Biomarker Deserving Attention
44. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
45. Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study
46. Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome
47. Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization
48. Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score
49. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure
50. STREAM characterisation correction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.